Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function.
Rituvanthikaa SeethapathyQiyu WangSophia ZhaoIan A StrohbehnJoshua D LongJames E DinulosDestiny HardenVinay B KadiyalaDaiana MorenoMeghan E SisePublished in: PloS one (2023)
Remdesivir use in patients with impaired kidney function (eGFR between 15 - 60 mL/min/1.73m2) who present to the hospital with COVID-19 is not associated with increased risk of adverse kidney outcomes.